Literature DB >> 18437602

Thalidomide: mechanisms of action.

Taraneh Paravar1, Delphine J Lee.   

Abstract

The classification of thalidomide as an orphan drug with anti-inflammatory actions has led to its off-label use in conditions refractory to other medications. Although the observed clinical effects of thalidomide suggest it to have immunomodulatory capabilities, the mechanism of action is unclear. Here we review both the positive and negative studies of thalidomide at the bench in order to improve our understanding of the possible mechanisms of this drug in treating a variety of diseases at the bedside. Studies on the effects of thalidomide on the innate and adaptive immune system as well as tumorigenesis and angiogenesis are discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18437602     DOI: 10.1080/08830180801911339

Source DB:  PubMed          Journal:  Int Rev Immunol        ISSN: 0883-0185            Impact factor:   5.311


  25 in total

1.  A transgenic, mesodermal specific, Dkk1 mouse model recapitulates a spectrum of human congenital limb reduction defects.

Authors:  Filemon Dela Cruz; Melissa Terry; Igor Matushansky
Journal:  Differentiation       Date:  2012-03-08       Impact factor: 3.880

Review 2.  Growth factor and signaling pathways and their relevance to prostate cancer therapeutics.

Authors:  Jocelyn L Wozney; Emmanuel S Antonarakis
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

3.  Lenalidomide alone or lenalidomide plus dexamethasone significantly inhibit IgG and IgM in vitro... A possible explanation for their mechanism of action in treating multiple myeloma.

Authors:  E Shannon; F Sandoval; N Greig; P Stagg
Journal:  Int Immunopharmacol       Date:  2012-01-11       Impact factor: 4.932

Review 4.  Targeting angiogenesis for the treatment of prostate cancer.

Authors:  Emmanuel S Antonarakis; Michael A Carducci
Journal:  Expert Opin Ther Targets       Date:  2012-03-13       Impact factor: 6.902

5.  Angiogenesis inhibitors in the treatment of non-small cell lung cancer.

Authors:  Joline S W Lind; Egbert F Smit
Journal:  Ther Adv Med Oncol       Date:  2009-09       Impact factor: 8.168

Review 6.  Angiogenesis inhibitors in the treatment of prostate cancer.

Authors:  Paul G Kluetz; William D Figg; William L Dahut
Journal:  Expert Opin Pharmacother       Date:  2010-02       Impact factor: 3.889

7.  Hair repigmentation associated with thalidomide use for the treatment of multiple myeloma.

Authors:  Stephanie Lovering; Wenya Miao; Toni Bailie; Dominick Amato
Journal:  BMJ Case Rep       Date:  2016-07-21

Review 8.  Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs).

Authors:  Peter H Wiernik
Journal:  Curr Treat Options Oncol       Date:  2008-11-19

9.  Thalidomide effect in endothelial cell of acute radiation proctitis.

Authors:  Ki-Tae Kim; Hiun-Suk Chae; Jin-Soo Kim; Hyung-Keun Kim; Young-Seok Cho; Whang Choi; Kyu-Yong Choi; Sang-Young Rho; Suk-Jin Kang
Journal:  World J Gastroenterol       Date:  2008-08-14       Impact factor: 5.742

10.  Systemic Injection of Thalidomide Prevent and Attenuate Neuropathic Pain and Alleviate Neuroinflammatory Response in the Spinal Dorsal Horn.

Authors:  Hao Xu; Sha-Jie Dang; Yuan-Yuan Cui; Zhen-Yu Wu; Jun-Feng Zhang; Xiao-Peng Mei; Yu-Peng Feng; Yun-Qing Li
Journal:  J Pain Res       Date:  2019-11-29       Impact factor: 3.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.